The report notes an EBITDA beat driven by volume and realization growth and reiterates BUY with a raised target price.
Read this note →Dr. Lal Path Labs Ltd.
NSE LALPATHLAB BSE 539524 INE600L01024
0 filings · 0 analysed
2,016.50
+29.43%
over 5 years
-
HSIE Results Daily 05 Nov 26 HSIE
The report notes an EBITDA beat driven by volume and realization growth and reiterates BUY with a raised target price.
-
The report highlights network expansion, genomics investments, and projected FY26-28E CAGRs, setting a target of ₹2,240 with a bullish technical trendline breakout view.
-
Dr Lal Pathlabs Update Oct 26 HSIE
The report maintains a BUY rating with a revised target price of INR 2,220 (based on 46x Q2FY29E EPS), citing steady volume-led growth, margin stability around 29.2-29.3%, wellness segment traction, and recent M&As in genomics (SN Gene) and international markets (Sunshine Healthcare, Ghana).
-
Pharma and Healthcare Q2FY27 Preview HSIE
The report expects 17% YoY revenue growth with volume-led gains and margin expansion, naming it a strong performer.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 05 Nov 2026, 06:50 | long | 2,029.40 | 2,330.00 | 1,970.00 | -20% | open by 2027-11-05 |
| HDFC Securities | 09 Oct 2026, 10:20 | long | 1,933.60 | 2,220.00 | 1,970.00 | 13% | open by 2027-10-09 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 1,945.10 | 2,080.00 | 1,970.00 | 18% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report highlights network expansion, genomics investments, and projected FY26-28E CAGRs, setting a target of ₹2,240 with a bullish technical trendline breakout view.
Read this note →The report maintains a BUY rating with a revised target price of INR 2,220 (based on 46x Q2FY29E EPS), citing steady volume-led growth, margin stability around 29.2-29.3%, wellness segment traction, and recent M&As in genomics (SN Gene) and international markets (Sunshine Healthcare, Ghana).
Read this note →The report expects 17% YoY revenue growth with volume-led gains and margin expansion, naming it a strong performer.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief